Adellgene®

Adellgene® line is a products range based on fragment analysis technology, in which DNA is amplified by conventional PCR and separated by capillary electrophoresis in a genetic sequencer. This technology allows to quantify the number of triplet repeats so as to classify genotypically a given sample. This product line is focused on rare diseases, being a very good CE solution for genetic laboratories.

Adellgene® Fragile X

Kit for the determination of healthy, premutation and mutant alleles in the FMR1 gene by fluorescent fragment analysis
See product

Adellgene® Fragile X Screening

Kit for the determination of healthy and premutation alleles in the FMR1 gene by fluorescent fragment analysis
See product

Adellgene® Friedreich’s Ataxia

Kit for the determination of the GAA triplet repeats number of the FXN gene by fluorescent fragment analysis
See product

Adellgene® Myotonic Dystrophy Confirmatory

Kit for the determination of the CTG triplet repeats number of the DMPK gene by fluorescent fragment analysis
See product

Adellgene® Myotonic Dystrophy Screening

Kit for the determination of the CTG triplet repeats number of the DMPK gene by fluorescent fragment analysis
See product

Adellgene® SCAs

Kit for the determination of the CAG and CTA/CTG triplet repeats number (SCAs 1, 2, 3, 6, 7 and SCA 8, respectively) by fluorescent fragment analysis
See product

Adellgene® Huntington Disease

Kit for the determination of the CAG triplet repeats number of the HTT gene by fluorescent fragment analysis
See product

About Adellgene®

BDR and Adellgene® are part of Orphanet, a global multi-stakeholder consortium from 41 countries, which aims to provide high quality information on rare diseases and to ensure equitable access to knowledge for all stakeholders.

Orphanet is a unique resource that gathers and updates knowledge on rare diseases in order to improve the diagnosis, care and treatment of patients with rare diseases.

We advise you

Basic information about data protection

In compliance with the provisions in the regulation General of protection of data 2016/679, BLACKHILLS DIAGNOSTIC RESOURCES, S.L.U. informs that its e-mail address, as well as other personal data that may be included in this form form part of a treatment of personal data whose features are detailed below:

  • Responsible: BLACKHILLS DIAGNOSTICS RESOURCES
  • Purpose: Answer the queries raised by the user and send the requested information
  • Legitimation: User consent
  • Addressee: Assignments are only made if there is a legal obligation.
  • Rights: Access, rectify and delete, as well as other rights, as indicated in the
    privacy policy

 

For further information, please refer to our Privacy Policy.

BDR

CE-IVD

Company

European Regional Development Fund
A way to make Europe

Products

Clients

Cookies consent